Background: Antiparkinsonian pharmacotherapy represents one of the most important expenses related to Parkinson's disease. The application of generic drugs may help to reduce the economic burden of the disease; however, efficacy and safety of these products have been less studied. Objective: To investigate the efficacy and safety of generic rasagiline (Ralago ® ) from a clinical perspective. Methods: The Clinical Global Impression of Severity scale was used to rate the most important motor and non-motor symptoms at baseline and 12 weeks after the initiation of Ralago ® . Patients also identified symptoms which were the main sources of their disability and distress in everyday life. Results: A total of 499 patients were enrolled (231 females, mean age: 73.2 ± 9.1 years, mean duration of disease: 3.6 ± 3.7 years). Of them, 486 patients completed the study protocol. Both motor and non-motor symptoms showed improvement during 12-week Ralago ® treatment. Adverse events were rare, and the majority of them were not considered as serious. Conclusions: The generic rasagiline (Ralago ® ) is an effective and safe generic product.
Introduction
Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder characterized by a broad spectrum of both motor and non-motor symptoms meet the same or comparable standards [19] . Based on the recommendations of the European Medicines Agency, pharmaceutical equivalence in combination with the lack of significant difference in bioavailability is required to consider two medicinal products as bioequivalent [19] . According to current regulation, bioequivalence of a generic drug with the brand-name counterpart must be demonstrated to obtain a license for making the generic product commercially available [19] [20] . Furthermore, therapeutic equivalence seems to be also influenced by bioequivalence in combination with pharmaceutical equivalence [21] ; however, the accepted regulatory limits in bioequivalence studies [22] may be too permissive. Theoretically, an 80% -125% bioequivalence range for a generic drug compared to the branded originator might result in inappropriate control of Parkinsonian symptoms producing akinesia or dyskinesia. Therefore, studies are warranted to assess the efficacy and safety of generic antiparkinsonian drugs as it has been done by some previous clinical trials comparing branded and generic formulations [23] [27] [30] .
Generic drugs may also be pharmaceutical alternatives, medicinal products with the same active substance but in different salts or esters. In the European Union, several pharmaceutical alternatives exist, for example, amantadine-sulfate (PK-MERZ ® ), and amantadine-chlorate (e.g. Viregyt ). The majority of the generic products for rasagiline are also pharmaceutical alternatives containing rasagiline-tartrate instead of rasagiline-mesylate used in the branded counterpart.
Postmarketing studies on generic drugs are warranted, especially if they contain pharmacological alternative ingredients. Therefore, an open-label, multicenter, non-invasive, observational 12-week clinical trial was conducted on the effects of a generic antiparkinsonian drug containing rasagiline (Ralago ® , Krka, Slovenia).
Materials and Methods
The KPASES 04/2016-RALAGO/HU study of motor and non-motor symptoms in patients with Parkinson's disease after 12-week treatment with irreversible MAO-B inhibitor Ralago ® (rasagiline) was performed in Hungary. The study protocol was approved by the National Institute of Pharmacy and Nutrition (OGYÉI/1382-4/2017).
The active ingredient of the investigated product is rasagiline-tartrate. In addition to 1 mg of this active substance, the durg contains some additives including cellulose microcrytals, maize strach, silicon dioxid, talc, and stearic acid.
With the participation of 40 Hungarian movement disorders centers, those patients were enrolled in this study who presented at the included centers be- or nursing were exclusion criteria. Originally, the enrollment of 500 patients with PD was planned, however, a total of 499 was achieved within the planned timeframe.
At baseline (Visit 1), demographic, medication, and disease-related data were recorded. The severity of motor and non-motor symptoms, including bradykinesia, rigidity, tremor, postural instability, daytime sleepiness, fatigue, mood disturbances, psychosis, memory disturbances, social difficulties, sexual dysfunction, urinary problems, olfactory disturbances, and pain, were rated by clinicians using the Clinical Global Impression of Severity (CGI-S) scale (0 = normal; 1 = mild; 2 = moderate; 3 = severe, and 4 = very severe) [24] . Besides, patients were asked to identify the three symptoms which were the main sources of disability and distress in everyday life.
12 weeks after the initiation of Ralago ® treatment (Visit 2), clinicians reevaluated both the motor and NMS of the disease. Data of patients underwent both the baseline and the 12-week follow-up examinations were used for the evaluation of antiparkinsonian efficacy of Ralago ® . The safety profile of the product was evaluated based on data of all enrolled patients.
Although the study was sponsored by Krka (Slovenia), the pharmaceutical company producing Ralago ® , data analysis was completely independent of the sponsor. The IBM SPSS software package (version 24.0., IBM Inc, Armonk, NY, USA) was used for statistical analysis. Because the variables did not follow the normal distribution, Wilcoxon's signed rank test was used during comparison of the two visits. The level of statistical significance was set at 0.05.
Results
A total of 499 patients were enrolled with computable data for Visit 1 (231 females, mean age at baseline: 73.2 ± 9.1 years, mean disease duration at baseline: 3.6 ± 3.7 years). Demographic-, medication-, and disease-related data of patients at Visit 1 are shown in Table 1 . Most of the patients (89.7%) were between 60 and 90 years of age. Numbers of enrolled males (53.7%) and females (46.3%) were roughly equal. Nearly all the subjects (99.6%) were Caucasian. Two-thirds of the patients had a 1 to 5-year history of PD, and 17.4% of them suffered from motor fluctuations at baseline. 100 patients (20.0%) received no specific antiparkinsonian medication at the enrollment.
Comparing medication data at Visit 1 and Visit 2, the initiation of Ralago ® led to a slight reduction in the application of other antiparkinsonian drugs in the study population. Medication data of patients at Visit 2 are represented in Table 2 . Safety data analysis was performed on the whole population (study population, n = 499); whereas, the efficacy calculations were based on the data of 486 patients who underwent both the Visit 1 and the Visit 2 (efficacy population). Data of thirteen patients could not be inlcuded in efficacy analysis because of According to CGI-S ratings, Ralago ® significantly improved all the cardinal motor symptoms of PD, including tremor, bradykinesia, and rigidity; moreover, it also had beneficial effects on postural instability. Besides, a significant reduction was found in the severity of all examined NMS-with the exception of psychosis-after 12 weeks of Ralago ® treatment (Table 3) . The number of patients experiencing any changes is demonstrated in Table 4 . These data show that the use of Ralago ® was associated with significantly higher rates of improvement than worsening in both motor and NMS.
Half of the included patients (50.4%) reported fatigue among the three most disabling symptoms in everyday life, followed by bradykinesia (48.6%) and tremor (48.3%). The same symptoms were most frequently reported among the three main sources of distress in daily living. Psychosis, olfactory disturbances and sexual problems were most rarely responsible for disability and distress in everyday life (Table 5) .
A total of 37 AEs were reported in 31 patients. Of them, six AEs were serious (persistent incapacity due to lumbar vertebral fracture in one case and death in five cases). Based on the judgment of the physician, these events were not associated with the use of Ralago ® . The main underlying cause of death could be the high mean age of the study cohort (cardiovascular and cerebrovascular events, n = 5). The most common non-serious AEs were gastrointestinal disturbances, including stomachache, meteorism, and abdominal spasms;
worsening of tremor; sleep disturbances; dizziness; urinary problems such as incontinence and strangury; and agitation or hallucinations. Of the non-serious AEs, 19 events were considered to be in association with Ralago ® treatment, and most of them completely disappeared after the discontinuation of the drug (Table 6 ). 
Discussion
To the best of our knowledge, this is the first study evaluating the efficacy and However, this approach may not translate into clinical efficacy and safety [25] .
In advanced PD, the theoretical ± 20% difference for the plasma levels may imply more frequent or severe peak of dose dyskinesia and OFF symptoms. There- Therefore, it was suggested that generic drugs may not be eligible for treatment of a subgroup of PD patients [26] . the patients did not prefer either formulation after completing the study protocol which might be due to the fact that the time with "good periods" remained comparable between the Requip modutab ® and Ralnea ® treatment [23] .
Similarly, the results of our present study also support the efficacy and safety of generic rasagiline, Ralago ® . It seems to have beneficial effects on the control of both the early cardinal motor symptoms of PD and other disabling motor features emerging in later stages of the disease, such as postural instability. Furthermore, Ralago ® also appears to own the previously described ability of rasagiline to beneficially influence the severity of NMS in PD [12] [13] . Some previous studies have found that rasagiline may improve HRQoL [7] [31]. By alleviating symptoms reported to be the main sources of disability and distress in everyday life (fatigue, bradykinesia, and tremor), Ralago ® may also be able to improve HRQoL.
The safety profile of the product can also be considered very good. Adverse events were rare (n = 37), and most of them were considered as non-serious. The half of all adverse events-including all the serious adverse events (n = 6)-were not in association with Ralago ® treatment. Adverse events related to the drug completely disappeared after withdrawal. Comparing the results of safety analysis of this study to those of other clinical trials investigating other rasagiline-containing products [7] [10] [31] concerning frequency and severity of adverse events, the safety profile of Ralago ® seems to be somewhat better. As PD usually occurs in the older population which is more prone to be affected by side effects of pharmacotherapy because of polimorbidity and drug interactions, antiparkinsonian medications with higher safety should be preferred in these patients. Based on the results of the present study, Ralago ® can be used safely in The strength of this study lies in the high number of enrolled PD patients and the longitudinal study design. However, one of the most important limitations is the lack of utilization of a well-established PD-specific rating scale (e.g.,
MDS-UPDRS).
Because of the time constraints in the majority of the examination sites, the CGI-S was chosen as the main outcome measure. It is a valid and reliable tool for assessing severity of symptoms [32] and has previously been used in other studies [8] [33] [34] . Another issue may be that the study did not include a control group, therefore, potential effects of some factors (e.g., placebo effect) on our findings cannot be definitely excluded. Furthermore, only patients of Hungarian movement disorders centers were enrolled, so certain effects of Ralago ® (e.g., interactions with medications which are not available in Hungary) might have remained unexplored. Finally, the study lasted only 12 weeks, therefore, future studies are needed to establish long-term efficacy and safety of Ralago ® in the Hungarian population.
Conclusion
To conclude, Ralago ® was efficiently used as a monotherapy or as adjunctive therapy to other antiparkinsonian medications to improve symptomatic control in the Hungarian population suffering from PD. Beside its efficacy, Ralago ® also had a very good safety profile which makes the product highly eligible for the safe pharmacotherapy of PD subjects being often elderly patients. As Ralago ® seems to be able to improve a broad spectrum of disabling symptoms of PD, it may also have beneficial effects on HRQoL. Based on the results of the present study, Ralago ® can be considered as a clinically useful generic product in the pharmacotherapy of PD.
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